Lv12
30 积分 2024-09-01 加入
Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo
5小时前
已完结
Characterization of Anti-CD3 Antibodies in Clinically Available Bispecific T Cell Engagers
1天前
已完结
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
6天前
已完结
Patient Values and Preferences in Chronic Urticaria Treatment
7天前
已完结
Single-cell and spatial transcriptome analysis reveals the cellular heterogeneity of liver metastatic colorectal cancer
24天前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
25天前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
25天前
已完结
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study
1个月前
已完结
皖公网安备34019202002308
